RAUVAL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RAUVAL (RAUVAL).
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
| Metabolism | Metabolized in the liver via CYP450 enzymes, primarily CYP3A4, to active and inactive metabolites. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%. |
| Half-life | Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment. |
| Protein binding | 85-90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-1.0 L/kg; indicates extensive extravascular distribution. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes. |
| Duration of Action | Oral: 8-12 hours; Intravenous: 4-8 hours; clinical effects correlate with plasma levels. |
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, dose reduction by 50% is recommended. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Use with caution; maximum 1.5 mg daily. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years. |
| Geriatric use | Start at 1 mg orally once daily; consider slower titration due to increased sensitivity to orthostatic hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RAUVAL (RAUVAL).
| Breastfeeding | Rauval is excreted in human milk; potential for serious adverse reactions in nursing infants. M/P ratio unknown. Breastfeeding is contraindicated. |
| Teratogenic Risk | First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairment. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to rauwolfia serpentina or any component","Active peptic ulcer disease","Ulcerative colitis","History of mental depression, especially with suicidal tendencies","Electroconvulsive therapy (ECT) within 7 days"]
| Precautions | ["May cause mental depression, especially at high doses, and should be discontinued if signs of depression appear.","Use with caution in patients with a history of peptic ulcer disease as it increases gastric acid secretion.","May cause orthostatic hypotension, tachycardia, and electrolyte disturbances.","Abrupt discontinuation may lead to withdrawal symptoms such as agitation, anxiety, and hypertension."] |
Loading safety data…
| Monitor maternal blood pressure, renal function, and fetal growth via ultrasound. Assess amniotic fluid volume regularly. |
| Fertility Effects | Rauval may cause reversible infertility in females due to anovulation and in males due to impaired spermatogenesis. |